Isis Pharmaceuticals, Inc.

Genzyme Corporation

Atlantic Pharmaceuticals (holdings) Limited

Mark K Wedel

Richard S Geary

Diane Tribble

Zhengrong Yu

Phillip B Miner

Philip P Miner, Jr

Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.

Administering antisense oligonucleotides complementary to human apolipoprotein B

Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5'-GCCCAAGCTGGCATCCGTCA-3&#x2032;, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days) after the conclusion of the administration of the composition. The composition is well tolerated and systemic exposure is minimal.

Therapeutic antisense oligonucleotide compositions for the treatment of inflammatory bowel disease

The present invention relates methods of treating pouchitis by administering a pharmaceutical formulation suitable for rectal use, such as an enema or suppository, comprising an antisense oligonucleotide targeted to ICAM-1 to an individual

Compositions and methods for treatment of pouchitis

The present invention relates methods of treating pouchitis by administering a pharmaceutical formulation suitable for rectal use, such as an enema or suppository, comprising an antisense oligonucleotide targeted to ICAM-1 to an individual.

Growing community of inventors

Temecula, CA, United States of America

Mark K Wedel